{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:29Z","timestamp":1793442689252,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973271"],"award-info":[{"award-number":["81973271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115413","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:15:20Z","timestamp":1790291720000},"page":"115413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Physiologically adaptive prodrug liposomal nanoplatform enables programmable biointerface switching to potentiate cold tumor immunotherapy"],"prefix":"10.1016","volume":"399","author":[{"given":"Yuanyuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutong","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115413_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091365","article-title":"Cationic liposomes as vectors for nucleic acid and hydrophobic drug therapeutics","volume":"13","author":"Ewert","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115413_bb0010","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles \u2013 from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115413_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115413_bb0020","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115413_bb0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115413_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: a strategy for overcoming the \u201cPEG dilemma\u201d in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115413_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115413_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115413_bb0045","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/adfm.201504780","article-title":"Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer","volume":"26","author":"Su","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.115413_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202508121","article-title":"Tuning the functional properties of nanocarriers using tunable nano-biointerfaces","volume":"36","author":"Pancaro","year":"2026","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.115413_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.01.070","article-title":"Biomimetic and personalized nanovaccines in cancer immunotherapy: design innovations, translational challenges, and future directions","author":"Xu","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.jconrel.2026.115413_bb0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2008.05.009","article-title":"Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives","volume":"130","author":"Xu","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115413_bb0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jconrel.2026.115413_bb0070","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115413_bb0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115413_bb0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115413_bb0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","article-title":"Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115413_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00360","article-title":"Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?","volume":"5","author":"Bruttel","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0100","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115413_bb0105","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1158\/0008-5472.CAN-06-1690","article-title":"All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients","volume":"66","author":"Mirza","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115413_bb0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejps.2017.02.021","article-title":"All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase","volume":"103","author":"Kuroda","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115413_bb0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.trecan.2023.11.009","article-title":"Targeting myeloid cells for cancer immunotherapy: Siglec-7\/9\/10\/15 and their ligands","volume":"10","author":"Boelaars","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2026.115413_bb0120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","article-title":"Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2","volume":"21","author":"Wieboldt","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0005-2736(01)00290-5","article-title":"Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties","volume":"1512","author":"Campbell","year":"2001","journal-title":"Biochim. Biophys. Acta (BBA) Biomembranes"},{"key":"10.1016\/j.jconrel.2026.115413_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114045","article-title":"An in vivo combined induction strategy of whole cancer cell vaccines triggers systemic immunity to eradicate triple-negative breast cancer","volume":"385","author":"Lu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115413_bb0135","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","article-title":"PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective","volume":"34","author":"Tenchov","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115413_bb0140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","article-title":"Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes","volume":"105","author":"Ishida","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115413_bb0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/glycob\/cwx026","article-title":"Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties","volume":"27","author":"Yu","year":"2017","journal-title":"Glycobiology"},{"key":"10.1016\/j.jconrel.2026.115413_bb0150","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBP\u03b2 transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115413_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790317","article-title":"Siglec signaling in the tumor microenvironment","volume":"12","author":"van Houtum","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115413_bb0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"CDM"},{"key":"10.1016\/j.jconrel.2026.115413_bb0170","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115413_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1081\/LPR-64971","article-title":"Liposome opsonization","volume":"15","author":"Yan","year":"2005","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2026.115413_bb0180","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.omtm.2020.07.015","article-title":"Barriers and strategies of cationic liposomes for cancer gene therapy","volume":"18","author":"Liu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115413_bb0185","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115413_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18636-w","article-title":"Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer","volume":"11","author":"Kocher","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115413_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2024.154660","article-title":"Sepsis epidemiology and prognosis in cancer patients: preliminary results of a multicenter prospective observational study","volume":"81","author":"Ture","year":"2024","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.jconrel.2026.115413_bb0200","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0205","article-title":"Terminally exhausted CD8(+) T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0210","article-title":"CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation","volume":"17","author":"Zhou","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0215","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/acsnano.8b02481","article-title":"Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer","volume":"12","author":"Zhao","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115413_bb0220","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.jcmgh.2021.07.006","article-title":"Myeloid cell mediated immune suppression in pancreatic cancer","volume":"12","author":"Kemp","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115413_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.115413_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245857","article-title":"Navigating the immune maze: pioneering strategies for unshackling cancer immunotherapy resistance","volume":"15","author":"Yao","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115413_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12630","article-title":"ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion","volume":"7","author":"Chronopoulos","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115413_bb0240","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1073\/pnas.0705395105","article-title":"Progenitor\/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling","volume":"105","author":"Tang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115413_bb0245","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1021\/acsnano.7b08148","article-title":"Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel","volume":"12","author":"Jin","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115413_bb0250","article-title":"Durable protective efficiency provide by mRNA vaccines require robust immune memory to antigens and weak immune memory to lipid nanoparticles","volume":"25","author":"Tang","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2026.115413_bb0255","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNF \u03b1 and IFN \u03b3: a comprehensive review","volume":"51","author":"Shen","year":"2018","journal-title":"Cell Prolif."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:45:34Z","timestamp":1793439934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S0168365926008175"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115413","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically adaptive prodrug liposomal nanoplatform enables programmable biointerface switching to potentiate cold tumor immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115413"}}